Printer Friendly

ALAMAR BIOSCIENCES APPOINTS NEW ADDITION TO BOARD OF DIRECTORS

 SACRAMENTO, Calif., Jan. 28 /PRNewswire/ -- Alamar Biosciences Inc. (NASDAQ: ALMRU), a research and development company involved in producing and marketing in vitro diagnostic tests, expanded its board of directors and has named a new member, the company announced today.
 Joseph L. Schocken, president of Broadmark Capital Corp. and Broadmark Holdings Inc., in Seattle, was named as the ninth member of the board of directors in November 1992. Schocken founded The Broadmark Group in 1986, to provide investment banking services to middle-market Northwest companies. He is an active investor with holdings in several high technology, shipping, manufacturing and real estate companies.
 Prior to Broadmark, Schocken was a partner in Weatherly Private Capital Inc. of Bellevue, Wash. Weatherly is a private investment banking company.
 Alamar's full nine-member board of directors also includes: Kenneth D. Miller, chief executive officer of Alamar; Michael V. Lancaster, Ph.D., president and co-founder of Alamar; Rebecca D. Fields, Ph.D., executive vice president, chief scientific officer and co-founder of Alamar; John H. Abeles, M.D., president of MedVest Inc., a medical consulting and venture capital company; Jack H. Halperin, M.D., an independent corporate attorney specializing in venture capital financing; Joel S. Kanter, president of Windy City Inc., an investment management and advisory firm; Charles J. Soderquist, Ph.D., president of the Sacramento Center for Technology Development Inc.; a business incubator for start-up technology companies; and Henry T. Wilson, vice president of Northwood Ventures, a venture capital investment partnership and principal shareholder in Alamar.
 Alamar Biosciences Inc. is traded on NASDAQ under the symbol ALMRU. The company develops, manufactures and markets in vitro disposable testing products for hospitals, reference laboratories and other health care providers. Alamar currently markets bacterial identification and antibiotic dosage effectiveness test kits and alamar Blue(TM), an indicator dye for determining cell viability in research and biotechnology applications.
 -0- 1/28/93
 /CONTACT: Kenneth Miller, chief executive officer of Alamar, 916-567-3475; or Elizabeth Truax, 415-986-1591, or Kathy Brunson, 312-266-7800, both of the Financial Relations Board, for Alamar/
 (ALMRU)


CO: Alamar Biosciences Inc. ST: California IN: MTC SU: PER

GT-SG -- SF004 -- 0076 01/28/93 09:07 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 28, 1993
Words:354
Previous Article:CHART HOUSE POSTS FOURTH QUARTER RESULTS
Next Article:VERIFONE ANNOUNCES FOURTH-QUARTER RESULTS: NET INCOME UP 32.9 PERCENT ON REVENUE OF $62.5 MILLION; 32 CENTS EARNINGS PER SHARE
Topics:


Related Articles
ALAMAR BIOSCIENCES REPORTS YEAR-END RESULTS
ALAMAR ANNOUNCES THE HIRING OF FIRST SALES FORCE
ALAMAR BIOSCIENCES ANNOUNCES SIGNED SCLAVO AGREEMENT;
ALAMAR BIOSCIENCES RECEIVES LAST PENDING FDA CLEARANCE; FULL PRODUCT LINE NOW AVAILABLE WORLDWIDE
ALAMAR BIOSCIENCES RAISES MORE FUNDS THAN EXPECTED THROUGH PRIVATE FINANCING;
ALAMAR BIOSCIENCES SIGNS LETTER OF INTENT TO MERGE WITH ACCUMED, INC.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters